FDA approves Blenrep for relapsed or refractory multiple myeloma

Published Date: 31 Oct 2025

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

2.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

3.

Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.

4.

Gene therapy for glioblastoma is effectively created by researchers.

5.

Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot